What's Happening?
IQVIA, a global leader in clinical research services, is advocating for a shift in how trial sponsors select countries for clinical trials. Rebecca Sayers, the senior director and global head of site enablement solutions at IQVIA, discussed with pharmaphorum
the importance of moving from static country lists to a more consultative patient solution strategy. This approach emphasizes the integration of feasibility, population insight, and site reality early in the planning stages. The goal is to mitigate recruitment and delivery risks by aligning patient populations, experienced investigators, and operational readiness before countries are selected for trials. This strategy is part of IQVIA's broader commitment to using AI responsibly and delivering high-quality health data and insights to improve patient outcomes.
Why It's Important?
The approach proposed by IQVIA is significant as it addresses common challenges in clinical trials, such as recruitment issues and delivery risks, which often stem from early decisions about trial locations. By focusing on patient population insights and site readiness, sponsors can enhance the efficiency and success rates of clinical trials. This strategy not only benefits the sponsors by reducing risks and costs but also accelerates the development of medical treatments, ultimately improving patient outcomes. The emphasis on early engagement and global site intelligence can lead to more informed decision-making, potentially transforming how clinical trials are conducted globally.
